Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Adolescent
Antigens, CD19
/ administration & dosage
Child
Child, Preschool
Humans
Immunotherapy, Adoptive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Receptors, Antigen, T-Cell
/ genetics
Receptors, Chimeric Antigen
/ genetics
Recurrence
T-Lymphocytes
/ pathology
Exome Sequencing
Young Adult
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
24
01
2019
accepted:
17
07
2019
pubmed:
4
9
2019
medline:
13
11
2019
entrez:
4
9
2019
Statut:
ppublish
Résumé
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL)
Identifiants
pubmed: 31477906
doi: 10.1038/s41591-019-0549-5
pii: 10.1038/s41591-019-0549-5
doi:
Substances chimiques
Antigens, CD19
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Banques de données
ClinicalTrials.gov
['NCT02443831']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1408-1414Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/D014301/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/E005896/1
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR-RP-R3-12-001
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Références
Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).
doi: 10.1016/S0140-6736(14)61403-3
Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest 126, 2123–2138 (2016).
doi: 10.1172/JCI85309
Gardner, R. A. et al. Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322–3330 (2017).
doi: 10.1182/blood-2016-10-748772
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
doi: 10.1056/NEJMoa1709866
Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018).
doi: 10.1056/NEJMoa1709919
Qin, H. et al. Novel CD19/CD22 bicistronic chimeric antigen receptors outperform single or bivalent cars in eradicating CD19+CD22+, CD19- and CD22- Pre-B Leukemia. Blood 130, 810 (2017).
Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res 19, 3153–3164 (2013).
doi: 10.1158/1078-0432.CCR-13-0330
Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453–1464 (2009).
doi: 10.1038/mt.2009.83
Schmid, D. A. et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184, 4936–4946 (2010).
doi: 10.4049/jimmunol.1000173
Thomas, S. et al. Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood 118, 319–329 (2011).
doi: 10.1182/blood-2010-12-326736
Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P. & Abken, H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J. Immunol. 173, 7647–7653 (2004).
doi: 10.4049/jimmunol.173.12.7647
Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676–684 (2004).
doi: 10.1038/sj.leu.2403302
Kowolik, C. M. et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66, 10995–11004 (2006).
doi: 10.1158/0008-5472.CAN-06-0160
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).
doi: 10.1182/blood-2014-05-552729
Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664–679 (2016).
doi: 10.1158/2159-8290.CD-16-0040
Maude, S. L. et al. Chimeric antigen receptor t cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
doi: 10.1056/NEJMoa1407222
Liu, X. et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 75, 3596–3607 (2015).
doi: 10.1158/0008-5472.CAN-15-0159
Park, S. et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci. Rep. 7, 70 (2017).
doi: 10.1038/s41598-017-00171-2
Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
doi: 10.1126/scitranslmed.3008226
Maude, S. L. et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. J. Clin. Oncol. 34, 3011 (2016).
doi: 10.1200/JCO.2016.34.15_suppl.3011
Mueller, K. T. et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130, 2317–2325 (2017).
doi: 10.1182/blood-2017-06-786129
Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).
doi: 10.1038/nm.3838
Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
doi: 10.1126/scitranslmed.3005930
Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504–1506 (2018).
doi: 10.1038/s41591-018-0146-z
Almåsbak, H. et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene. Ther. 22, 391–403 (2015).
doi: 10.1038/gt.2015.4
Zola, H. et al. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol. 69, 411–422 (1991).
doi: 10.1038/icb.1991.58
Donnelly, M. L. et al. The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J. Gen. Virol. 82, 1027–1041 (2001).
doi: 10.1099/0022-1317-82-5-1027
Niesen, F. H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221 (2007).
doi: 10.1038/nprot.2007.321
Lugthart, G. et al. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. J. Immunother. 35, 42–53 (2012).
doi: 10.1097/CJI.0b013e31823569e2
Ricciardelli, I. et al. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 124, 2514 (2014).
doi: 10.1182/blood-2014-01-553362
Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463–8471 (1998).
pubmed: 9765382
pmcid: 110254
Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591–594 (2018).
doi: 10.1038/s41592-018-0051-x
Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strainw1118; iso-2; iso-3. Fly. (Austin) 6, 80–92 (2012).
doi: 10.4161/fly.19695